Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in four major investor conferences this September. The events include:

• Wells Fargo 2024 Healthcare Conference in Boston (Sept 4)
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York (Sept 5)
• H.C. Wainwright 26th Annual Global Investment Conference in New York (Sept 9)
• 2024 Cantor Fitzgerald Global Healthcare Conference in New York (Sept 17)

The company will engage in fireside chats and presentations at these events. Live webcasts will be available on Kymera's website, with replays archived for later viewing.

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:

• Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET;
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 5 at 3:20 p.m. ET;
• H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 9 at 8:00 a.m. ET; and
• 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY on September 17 at 11:30 a.m. ET.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.

Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300

FAQ

What investor conferences will Kymera Therapeutics (KYMR) attend in September 2024?

Kymera Therapeutics will attend four investor conferences in September 2024: Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Cantor Fitzgerald Global Healthcare Conference.

When and where is Kymera Therapeutics (KYMR) presenting at the Wells Fargo 2024 Healthcare Conference?

Kymera Therapeutics is presenting at the Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4, 2024, at 3:00 p.m. ET.

How can investors access Kymera Therapeutics' (KYMR) conference presentations?

Investors can access live webcasts of Kymera Therapeutics' presentations under the 'News and Events' section in the Investors area of the company's website at www.kymeratx.com. Replays will also be available after the events.

What is Kymera Therapeutics' (KYMR) focus in biopharmaceutical development?

Kymera Therapeutics is focused on advancing a new class of small molecule medicines using targeted protein degradation (TPD) technology.